PMID- 37795578
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20240123
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 20
DP  - 2023 Oct
TI  - Roles of long noncoding RNA in triple-negative breast cancer.
PG  - 20365-20379
LID - 10.1002/cam4.6600 [doi]
AB  - INTRODUCTION: Long noncoding RNAs (lncRNAs) play crucial roles in regulating 
      various hallmarks in cancers. Triple-negative (Estrogen receptor, ER; Human 
      epidermal growth factor receptor 2, HER2; Progesterone receptor, PR) breast 
      cancer (TNBC) is the most aggressive form of breast cancers with a poor prognosis 
      and no available molecular targeted therapy. METHODS: We reviewed the current 
      literature on the roles of lncRNAs in the pathogenesis, therapy resistance, and 
      prognosis of patients with TBNC. RESULTS: LncRNAs are associated with TNBC 
      pathogenesis, therapy resistance, and prognosis. For example, lncRNAs such as 
      small nucleolar RNA host gene 12 (SNHG12), highly upregulated in liver cancer 
      (HULC) HOX transcript antisense intergenic RNA (HOTAIR), lincRNA-regulator of 
      reprogramming (LincRNA-ROR), etc., are aberrantly expressed in TNBC and are 
      involved in the pathogenesis of the disease. LncRNAs act as a decoy, scaffold, or 
      sponge to regulate the expression of genes, miRNAs, and transcription factors 
      associated with pathogenesis and progression of TNBC. Moreover, lncRNAs such as 
      ferritin heavy chain 1 pseudogene 3 (FTH1P3), BMP/OP-responsive gene (BORG) 
      contributes to the therapy resistance property of TNBC through activating ABCB1 
      (ATP-binding cassette subfamily B member 1) drug efflux pumps by increasing DNA 
      repair capacity or by inducing signaling pathway involved in therapeutic 
      resistance. CONCLUSION: In this review, we outline the functions of various 
      lncRNAs along with their molecular mechanisms involved in the pathogenesis, 
      therapeutic resistance of TBNC. Also, the prognostic implications of lncRNAs in 
      patients with TNBC is illustrated. Moreover, potential strategies targeting 
      lncRNAs against highly aggressive TNBC is discussed in this review.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Das, Plabon Kumar
AU  - Das PK
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
AD  - Institute for Glycomics, Griffith University, Gold Coast, Australia.
FAU - Siddika, Ayesha
AU  - Siddika A
AD  - Institute of Tissue Banking & Biomaterial Research, Atomic Energy Research 
      Establishment (AERE) Savar, Dhaka, Bangladesh.
FAU - Rashel, Khan Mohammad
AU  - Rashel KM
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
FAU - Auwal, Abdul
AU  - Auwal A
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
FAU - Soha, Kazi
AU  - Soha K
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
FAU - Rahman, Md Arifur
AU  - Rahman MA
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
FAU - Pillai, Suja
AU  - Pillai S
AD  - School of Biomedical Sciences, University of Queensland, Saint Lucia, Australia.
FAU - Islam, Farhadul
AU  - Islam F
AUID- ORCID: 0000-0001-5262-4702
AD  - Department of Biochemistry & Molecular Biology, Rajshahi University, Rajshahi, 
      Bangladesh.
AD  - Institute for Glycomics, Griffith University, Gold Coast, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231005
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Humans
MH  - *RNA, Long Noncoding/genetics/metabolism
MH  - *Triple Negative Breast Neoplasms/pathology
MH  - *MicroRNAs/genetics
MH  - Prognosis
MH  - Gene Expression Regulation, Neoplastic
PMC - PMC10652353
OTO - NOTNLM
OT  - chemotherapy resistance
OT  - long noncoding RNAs
OT  - pathogenesis
OT  - prognosis
OT  - radiotherapy resistance
OT  - targeted therapies
COIS- There is no conflict of interest among the authors.
EDAT- 2023/10/05 06:43
MHDA- 2023/11/27 12:43
PMCR- 2023/10/05
CRDT- 2023/10/05 04:43
PHST- 2023/09/02 00:00 [revised]
PHST- 2023/05/24 00:00 [received]
PHST- 2023/09/17 00:00 [accepted]
PHST- 2023/11/27 12:43 [medline]
PHST- 2023/10/05 06:43 [pubmed]
PHST- 2023/10/05 04:43 [entrez]
PHST- 2023/10/05 00:00 [pmc-release]
AID - CAM46600 [pii]
AID - 10.1002/cam4.6600 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Oct;12(20):20365-20379. doi: 10.1002/cam4.6600. Epub 2023 Oct 5.